

**REMARKS**

**I. AMENDMENTS TO SPECIFICATION AND CLAIMS**

In response to the Notice to Comply accompanied by the Office Action dated September 28, 2007, Applicant submits herewith amendments to page 34 of the specification and claims 98 and 108. Applicant has made said amendments to include SEQ ID Nos., which were previously provided in the original Sequence Listing submitted with the present application. No new matter is added.


## II. CONCLUSION

Applicant submits that all claims are patentably distinguishable over the prior art for the reasons explained above. As such, Applicant respectfully requests the Examiner reconsider and withdraw all rejections, and allow all claims.

Although no fees are believed due, the Commissioner for Patents is hereby authorized to charge the amount for any deficiency in any fees due with the filing of this paper, and credit any overpayment in any fees paid on the filing or during prosecution of this application to Deposit Account No. 50-0951.

Applicant is grateful for the Examiner's consideration of this matter. In light of the remarks above, Applicant respectfully requests the Amendments be entered, all rejections be withdrawn, and all claims be allowed. If the Examiner still has concerns as to the allowability of any claims, the Examiner is urged to telephonically contact the undersigned at the number below.

Respectfully submitted,

  
Nicholas J. Landau, Ph.D.  
Registration No. 57,120

AKERMAN SENTERFITT  
Esperante Building  
222 Lakeview Avenue, Suite 400  
West Palm Beach, Florida 33401-6183  
(516) 653-5000  
Date: 10/29/2007

<b>Notice to Comply</b>	<b>Application No.</b> 10/516,361	<b>Applicant(s)</b> ISLAM ET AL.	
	<b>Examiner</b> Mark Staples	<b>Art Unit</b> 1637	

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e). The correct SEQ ID NO:2 is present in the paper copy of the of the sequence listing only. Therefore a search of the correct sequence is not possible.
- ☒ 7. Other: See Office Action.

**Applicant Must Provide:**

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", **as well as an amendment specifically directing its entry into the application.**
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216 or (703) 308-2923

For CRF Submission Help, call (703) 308-4212 or 308-2923

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY**